Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma

Tamar Safra, Joseph Menczer, Rinat Molho Bernstein, Shulem Shpigel, Dianna Matcejevsky, Moshe J. Inbar, Abraham Golan, Dan Grisaru*, Tally Levy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Objective: To evaluate safety and outcome of weekly carboplatin and paclitaxel as the initial postoperative adjuvant chemotherapy for epithelial ovarian carcinoma (EOC) patients. Methods: Patients with stage IC-IV epithelial ovarian cancer (EOC) primary peritoneal or tubal carcinoma were enrolled in this phase II study. Intravenous carboplatin (area under the curve 2) and paclitaxel (80 mg/m2) were administered on days 1, 8, and 15 of a 28-day cycle for 6-8 cycles. Cytoreductive surgery was performed as primary treatment or after 3 cycles of weekly neoadjuvant chemotherapy, followed postoperatively by an additional 3 cycles of chemotherapy. Results: Sixty-four women (median age 65 years, range 39.9-82.8) were enrolled. Fifty-six of them (87.6%) were diagnosed with stage III-IV disease. Neutropenia was the most common hematological toxicity: 25% of the subjects had grade 3-4 neutropenia, 34.4% were supported by GCSF and 15.6% received epoetin. The majority (89%) of the patients had grade 1 and only 7.8% had grade 2 alopecia. 7.8% had grade 3 fatigue and 14.1% had grade 2 and 3.1% grade 3 neuropathy, none developed grade 4 neuropathy and only 6.3% had some residual neuropathy at > 6 months after treatment. With a median follow-up of 31.5 months (range 5.9-57.3), estimated median survival was 52.0 months and median progression-free survival 25.74 (8.4-57.3) months (95% CI, 21.2-30.3). Overall and complete response rates were 92.1% and 64.1% respectively. Conclusion: Weekly carboplatin and paclitaxel as the initial chemotherapy for EOC is a feasible and well tolerated regimen and should be further evaluated in a larger phase III study.

Original languageEnglish
Pages (from-to)215-218
Number of pages4
JournalGynecologic Oncology
Issue number2
StatePublished - Aug 2009
Externally publishedYes


  • Ovarian cancer
  • Toxicity
  • Weekly combined carboplatin and paclitaxel


Dive into the research topics of 'Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma'. Together they form a unique fingerprint.

Cite this